Switch to:
Also traded in: Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.51
NAS:WBA's Cash-to-Debt is ranked higher than
51% of the 338 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.50 vs. NAS:WBA: 0.51 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:WBA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.96 Max: No Debt
Current: 0.51
Equity-to-Asset 0.41
NAS:WBA's Equity-to-Asset is ranked lower than
51% of the 339 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.42 vs. NAS:WBA: 0.41 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:WBA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.41  Med: 0.57 Max: 0.64
Current: 0.41
0.41
0.64
Interest Coverage 9.48
NAS:WBA's Interest Coverage is ranked lower than
68% of the 396 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.23 vs. NAS:WBA: 9.48 )
Ranked among companies with meaningful Interest Coverage only.
NAS:WBA' s Interest Coverage Range Over the Past 10 Years
Min: 7.72  Med: 39.24 Max: No Debt
Current: 9.48
Piotroski F-Score: 5
Altman Z-Score: 3.86
Beneish M-Score: -2.86
WACC vs ROIC
8.93%
11.64%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 5.12
NAS:WBA's Operating Margin % is ranked higher than
73% of the 339 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.94 vs. NAS:WBA: 5.12 )
Ranked among companies with meaningful Operating Margin % only.
NAS:WBA' s Operating Margin % Range Over the Past 10 Years
Min: 4.51  Med: 5.31 Max: 6.05
Current: 5.12
4.51
6.05
Net Margin % 3.52
NAS:WBA's Net Margin % is ranked higher than
75% of the 340 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.78 vs. NAS:WBA: 3.52 )
Ranked among companies with meaningful Net Margin % only.
NAS:WBA' s Net Margin % Range Over the Past 10 Years
Min: 2.53  Med: 3.55 Max: 4.08
Current: 3.52
2.53
4.08
ROE % 13.70
NAS:WBA's ROE % is ranked higher than
71% of the 332 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.74 vs. NAS:WBA: 13.70 )
Ranked among companies with meaningful ROE % only.
NAS:WBA' s ROE % Range Over the Past 10 Years
Min: 9.67  Med: 14.63 Max: 19.24
Current: 13.7
9.67
19.24
ROA % 5.93
NAS:WBA's ROA % is ranked higher than
73% of the 342 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.31 vs. NAS:WBA: 5.93 )
Ranked among companies with meaningful ROA % only.
NAS:WBA' s ROA % Range Over the Past 10 Years
Min: 5.31  Med: 8.05 Max: 11.2
Current: 5.93
5.31
11.2
ROC (Joel Greenblatt) % 38.92
NAS:WBA's ROC (Joel Greenblatt) % is ranked higher than
85% of the 341 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.43 vs. NAS:WBA: 38.92 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:WBA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 24.31  Med: 29.67 Max: 39.26
Current: 38.92
24.31
39.26
3-Year Revenue Growth Rate 12.50
NAS:WBA's 3-Year Revenue Growth Rate is ranked higher than
83% of the 313 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.10 vs. NAS:WBA: 12.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:WBA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0.5  Med: 13.1 Max: 16.5
Current: 12.5
0.5
16.5
3-Year EBITDA Growth Rate 7.90
NAS:WBA's 3-Year EBITDA Growth Rate is ranked higher than
56% of the 281 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.20 vs. NAS:WBA: 7.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:WBA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -1.1  Med: 13.5 Max: 18.3
Current: 7.9
-1.1
18.3
3-Year EPS without NRI Growth Rate 12.70
NAS:WBA's 3-Year EPS without NRI Growth Rate is ranked higher than
67% of the 249 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.20 vs. NAS:WBA: 12.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:WBA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -12.1  Med: 14.1 Max: 20
Current: 12.7
-12.1
20
GuruFocus has detected 5 Warning Signs with Walgreens Boots Alliance Inc $NAS:WBA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:WBA's 10-Y Financials

Financials (Next Earnings Date: 2017-04-05)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

WBA Guru Trades in Q1 2016

Ray Dalio 32,760 sh (New)
Leucadia National 2,900 sh (New)
RS Investment Management 5,131 sh (+38.90%)
Ken Fisher 7,343 sh (+30.31%)
Jim Simons 648,000 sh (+21.53%)
Vanguard Health Care Fund 8,048,160 sh (+9.43%)
Mario Gabelli 384,296 sh (+4.99%)
Leon Cooperman 1,134,500 sh (+3.27%)
Tom Gayner 2,135,000 sh (unchged)
Bill Gates 3,475,398 sh (unchged)
Steven Romick Sold Out
Jeremy Grantham Sold Out
Louis Moore Bacon Sold Out
Steve Mandel Sold Out
John Griffin 2,406,000 sh (-2.98%)
Dodge & Cox 8,579 sh (-5.51%)
Mairs and Power 11,525 sh (-5.88%)
Keeley Asset Management Corp 3,125 sh (-13.19%)
Jana Partners 10,579,100 sh (-13.99%)
George Soros 25,558 sh (-14.81%)
Pioneer Investments 176,513 sh (-24.70%)
Joel Greenblatt 44,900 sh (-43.27%)
Paul Tudor Jones 11,872 sh (-46.65%)
Andreas Halvorsen 6,279,184 sh (-50.83%)
First Pacific Advisors 46,400 sh (-91.31%)
» More
Q2 2016

WBA Guru Trades in Q2 2016

Joel Greenblatt 470,385 sh (+947.63%)
Paul Tudor Jones 31,272 sh (+163.41%)
First Pacific Advisors 84,350 sh (+81.79%)
Mario Gabelli 450,074 sh (+17.12%)
Jim Simons 758,600 sh (+17.07%)
Leon Cooperman 1,222,900 sh (+7.79%)
Vanguard Health Care Fund 8,048,160 sh (unchged)
Tom Gayner 2,135,000 sh (unchged)
Keeley Asset Management Corp 3,125 sh (unchged)
Dodge & Cox 8,579 sh (unchged)
George Soros 25,558 sh (unchged)
Bill Gates 3,475,398 sh (unchged)
Ray Dalio Sold Out
RS Investment Management Sold Out
Leucadia National Sold Out
Pioneer Investments 175,350 sh (-0.66%)
Mairs and Power 11,445 sh (-0.69%)
Ken Fisher 6,449 sh (-12.17%)
John Griffin 1,681,000 sh (-30.13%)
Andreas Halvorsen 3,469,712 sh (-44.74%)
Jana Partners 4,579,100 sh (-56.72%)
» More
Q3 2016

WBA Guru Trades in Q3 2016

Joel Greenblatt 831,783 sh (+76.83%)
Pioneer Investments 229,753 sh (+31.03%)
Ken Fisher 6,726 sh (+4.30%)
First Pacific Advisors 86,550 sh (+2.61%)
Mario Gabelli 451,894 sh (+0.40%)
Vanguard Health Care Fund 8,048,160 sh (unchged)
Tom Gayner 2,135,000 sh (unchged)
Keeley Asset Management Corp 3,125 sh (unchged)
Mairs and Power 11,445 sh (unchged)
John Griffin 1,681,000 sh (unchged)
Dodge & Cox 8,579 sh (unchged)
George Soros 25,558 sh (unchged)
Bill Gates 3,475,398 sh (unchged)
Jana Partners Sold Out
Jim Simons Sold Out
Leon Cooperman 1,086,300 sh (-11.17%)
Andreas Halvorsen 1,191,911 sh (-65.65%)
Paul Tudor Jones 6,506 sh (-79.20%)
» More
Q4 2016

WBA Guru Trades in Q4 2016

Jim Simons 1,928,300 sh (New)
Larry Robbins 1,500,000 sh (New)
Andreas Halvorsen 7,899,951 sh (+562.80%)
Paul Tudor Jones 34,315 sh (+427.44%)
Ken Fisher 7,811 sh (+16.13%)
Mairs and Power 13,045 sh (+13.98%)
Vanguard Health Care Fund 8,048,160 sh (unchged)
Tom Gayner 2,135,000 sh (unchged)
Keeley Asset Management Corp 3,125 sh (unchged)
Bill Gates 3,475,398 sh (unchged)
John Griffin Sold Out
First Pacific Advisors Sold Out
George Soros Sold Out
Mario Gabelli 450,379 sh (-0.34%)
Dodge & Cox 8,079 sh (-5.83%)
Leon Cooperman 934,100 sh (-14.01%)
Joel Greenblatt 687,941 sh (-17.29%)
Pioneer Investments 182,995 sh (-20.35%)
» More
» Details

Insider Trades

Latest Guru Trades with WBA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers    NAICS: 446110    SIC: 5912
Compare: » details
Traded in other countries:W8A.Germany, WBA.Mexico, WBA.Switzerland, 0R0C.UK,
Walgreens Boots Alliance Inc operates drug-stores chain in the United States. It provides consumer goods and services, pharmacy, and health and wellness services through drug-stores, as well as mail, and by telephone and online.

Walgreens is one of the nation's largest retail pharmacies, with about 8,175 drugstores throughout the United States. This large network of stores allows the firm the ability to reach a significant portion of the U.S. population, providing excellent brand recognition. Prescription drugs account for about two thirds of sales, with the balance attributable to front-store products such as grocery, health, and beauty items. The firm also operates in-store health clinics.

Top Ranked Articles about Walgreens Boots Alliance Inc

Insider Buys Highlight for Week of Feb. 6 Insiders bought shares of Walgreens Boots Alliance and Qualcomm
Walgreens Boots Alliance Inc. (NASDAQ:WBA): Co-COO Ornella Barra bought 124,000 shares Read more...
Insider Trades Roundup: Arconic, Walgreens, Alphabet Reviewing the largest insider buys and sales of the week
The GuruFocus All-in-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$2,000,000+,” the duration to “February 2017” and All Insider Sales to “$5,000,000+.” Read more...
Walgreens, Rite Aid Reduce Price, Postpone Closing of Merger Deal’s value reduced by at least $2 billion
Walgreens Boots Alliance (NASDAQ:WBA) and Rite Aid Corp. (NYSE:RAD) announced on Monday they are reducing the price and postponing the close of their definitive merger agreement. Read more...
Weekly CEO Buys Insiders invest in Walgreens, American Assets, Heathcare Realty, General Electric, Triumph
According to GuruFocus’ Insider Data, these were the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
Weekly CEO Buys Highlights Insiders purchase Walgreens, Acushnet, New Media Investment, Omega Healthcare, Newell Brands
According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
Insider Invests in Walgreens Boots Alliance CEO purchases 2 million shares in company
Walgreens Boots Alliance Inc. (WBA) CEO, Executive Vice Chairman and 10% owner Stefano Pessina (Insider Trades) acquired 2 million shares in the company on Nov. 4. The price was $81.41 per share for a total transaction of $162,820,000. Read more...

Ratios

vs
industry
vs
history
PE Ratio 22.21
WBA's PE Ratio is ranked lower than
52% of the 424 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 21.03 vs. WBA: 22.21 )
Ranked among companies with meaningful PE Ratio only.
WBA' s PE Ratio Range Over the Past 10 Years
Min: 10.2  Med: 19.21 Max: 35.8
Current: 22.21
10.2
35.8
Forward PE Ratio 16.64
WBA's Forward PE Ratio is ranked higher than
65% of the 96 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.73 vs. WBA: 16.64 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 22.21
WBA's PE Ratio without NRI is ranked lower than
54% of the 332 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.66 vs. WBA: 22.21 )
Ranked among companies with meaningful PE Ratio without NRI only.
WBA' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.2  Med: 19.21 Max: 35.8
Current: 22.21
10.2
35.8
Price-to-Owner-Earnings 15.38
WBA's Price-to-Owner-Earnings is ranked higher than
62% of the 210 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 19.59 vs. WBA: 15.38 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
WBA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.76  Med: 16.31 Max: 40.18
Current: 15.38
8.76
40.18
PB Ratio 3.07
WBA's PB Ratio is ranked lower than
67% of the 433 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.91 vs. WBA: 3.07 )
Ranked among companies with meaningful PB Ratio only.
WBA' s PB Ratio Range Over the Past 10 Years
Min: 1.6  Med: 2.77 Max: 5.07
Current: 3.07
1.6
5.07
PS Ratio 0.78
WBA's PS Ratio is ranked lower than
64% of the 394 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.50 vs. WBA: 0.78 )
Ranked among companies with meaningful PS Ratio only.
WBA' s PS Ratio Range Over the Past 10 Years
Min: 0.36  Med: 0.65 Max: 1.1
Current: 0.78
0.36
1.1
Price-to-Free-Cash-Flow 14.54
WBA's Price-to-Free-Cash-Flow is ranked higher than
68% of the 200 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 21.37 vs. WBA: 14.54 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
WBA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.88  Med: 17.85 Max: 103.28
Current: 14.54
9.88
103.28
Price-to-Operating-Cash-Flow 11.94
WBA's Price-to-Operating-Cash-Flow is ranked lower than
53% of the 261 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.24 vs. WBA: 11.94 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
WBA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.44  Med: 11.88 Max: 21.27
Current: 11.94
6.44
21.27
EV-to-EBIT 16.75
WBA's EV-to-EBIT is ranked lower than
61% of the 436 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 15.27 vs. WBA: 16.75 )
Ranked among companies with meaningful EV-to-EBIT only.
WBA' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.3  Med: 12.8 Max: 25.1
Current: 16.75
6.3
25.1
EV-to-EBITDA 12.93
WBA's EV-to-EBITDA is ranked lower than
60% of the 447 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.34 vs. WBA: 12.93 )
Ranked among companies with meaningful EV-to-EBITDA only.
WBA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.9  Med: 10 Max: 18.8
Current: 12.93
4.9
18.8
PEG Ratio 5.55
WBA's PEG Ratio is ranked lower than
77% of the 166 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.13 vs. WBA: 5.55 )
Ranked among companies with meaningful PEG Ratio only.
WBA' s PEG Ratio Range Over the Past 10 Years
Min: 0.5  Med: 1.61 Max: 8.3
Current: 5.55
0.5
8.3
Shiller PE Ratio 29.18
WBA's Shiller PE Ratio is ranked lower than
66% of the 79 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 22.66 vs. WBA: 29.18 )
Ranked among companies with meaningful Shiller PE Ratio only.
WBA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 13.88  Med: 24.13 Max: 40.48
Current: 29.18
13.88
40.48
Current Ratio 1.50
WBA's Current Ratio is ranked higher than
64% of the 324 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.20 vs. WBA: 1.50 )
Ranked among companies with meaningful Current Ratio only.
WBA' s Current Ratio Range Over the Past 10 Years
Min: 1.19  Med: 1.62 Max: 2.36
Current: 1.5
1.19
2.36
Quick Ratio 0.94
WBA's Quick Ratio is ranked higher than
67% of the 324 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.70 vs. WBA: 0.94 )
Ranked among companies with meaningful Quick Ratio only.
WBA' s Quick Ratio Range Over the Past 10 Years
Min: 0.28  Med: 0.54 Max: 1.7
Current: 0.94
0.28
1.7
Days Inventory 39.15
WBA's Days Inventory is ranked lower than
51% of the 328 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 38.50 vs. WBA: 39.15 )
Ranked among companies with meaningful Days Inventory only.
WBA' s Days Inventory Range Over the Past 10 Years
Min: 35.11  Med: 53.52 Max: 60.84
Current: 39.15
35.11
60.84
Days Sales Outstanding 19.18
WBA's Days Sales Outstanding is ranked lower than
60% of the 249 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 13.60 vs. WBA: 19.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
WBA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.04  Med: 14.78 Max: 24.17
Current: 19.18
11.04
24.17
Days Payable 47.53
WBA's Days Payable is ranked higher than
51% of the 253 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 47.14 vs. WBA: 47.53 )
Ranked among companies with meaningful Days Payable only.
WBA' s Days Payable Range Over the Past 10 Years
Min: 28.73  Med: 34.47 Max: 48.01
Current: 47.53
28.73
48.01

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.77
WBA's Dividend Yield % is ranked lower than
55% of the 466 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.88 vs. WBA: 1.77 )
Ranked among companies with meaningful Dividend Yield % only.
WBA' s Dividend Yield % Range Over the Past 10 Years
Min: 0.54  Med: 1.71 Max: 3.11
Current: 1.77
0.54
3.11
Dividend Payout Ratio 0.39
WBA's Dividend Payout Ratio is ranked higher than
79% of the 290 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.77 vs. WBA: 0.39 )
Ranked among companies with meaningful Dividend Payout Ratio only.
WBA' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.16  Med: 0.31 Max: 0.64
Current: 0.39
0.16
0.64
3-Year Dividend Growth Rate 8.50
WBA's 3-Year Dividend Growth Rate is ranked higher than
57% of the 178 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.90 vs. WBA: 8.50 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
WBA' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 3.8  Med: 19.6 Max: 26
Current: 8.5
3.8
26
Forward Dividend Yield % 1.79
WBA's Forward Dividend Yield % is ranked lower than
55% of the 440 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.11 vs. WBA: 1.79 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.38
WBA's 5-Year Yield-on-Cost % is ranked higher than
57% of the 502 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.86 vs. WBA: 3.38 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
WBA' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.03  Med: 3.26 Max: 5.94
Current: 3.38
1.03
5.94
3-Year Average Share Buyback Ratio -4.60
WBA's 3-Year Average Share Buyback Ratio is ranked lower than
72% of the 195 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.60 vs. WBA: -4.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
WBA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -5  Med: -0.1 Max: 3.5
Current: -4.6
-5
3.5

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 20.58
WBA's Price-to-Tangible-Book is ranked lower than
97% of the 374 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.25 vs. WBA: 20.58 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
WBA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.94  Med: 4.66 Max: 58.76
Current: 20.58
1.94
58.76
Price-to-Intrinsic-Value-Projected-FCF 1.47
WBA's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
52% of the 272 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.52 vs. WBA: 1.47 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
WBA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.73  Med: 1.83 Max: 18.64
Current: 1.47
0.73
18.64
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.86
WBA's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
67% of the 87 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.48 vs. WBA: 1.86 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.20
WBA's Price-to-Median-PS-Value is ranked lower than
58% of the 381 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.14 vs. WBA: 1.20 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
WBA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.57  Med: 1.39 Max: 3.18
Current: 1.2
0.57
3.18
Price-to-Peter-Lynch-Fair-Value 4.34
WBA's Price-to-Peter-Lynch-Fair-Value is ranked lower than
87% of the 149 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.69 vs. WBA: 4.34 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
WBA' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.57  Med: 1.9 Max: 6.21
Current: 4.34
0.57
6.21
Price-to-Graham-Number 4.51
WBA's Price-to-Graham-Number is ranked lower than
89% of the 308 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.59 vs. WBA: 4.51 )
Ranked among companies with meaningful Price-to-Graham-Number only.
WBA' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.99  Med: 2.41 Max: 8.07
Current: 4.51
0.99
8.07
Earnings Yield (Greenblatt) % 5.96
WBA's Earnings Yield (Greenblatt) % is ranked lower than
55% of the 475 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.00 vs. WBA: 5.96 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
WBA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4  Med: 7.8 Max: 15.9
Current: 5.96
4
15.9
Forward Rate of Return (Yacktman) % 9.61
WBA's Forward Rate of Return (Yacktman) % is ranked higher than
59% of the 235 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.05 vs. WBA: 9.61 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
WBA' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7.1  Med: 14.6 Max: 23.7
Current: 9.61
7.1
23.7

More Statistics

Revenue (TTM) (Mil) $116,819
EPS (TTM) $ 3.77
Beta1.02
Short Percentage of Float1.18%
52-Week Range $75.74 - 88.00
Shares Outstanding (Mil)1,079.41

Analyst Estimate

Aug17 Aug18 Aug19
Revenue (Mil $) 120,611 127,186 137,690
EPS ($) 5.02 5.51 6.15
EPS without NRI ($) 5.02 5.51 6.15
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.56%
Dividends per Share ($) 1.48 1.53 1.70
» More Articles for WBA

Headlines

Articles On GuruFocus.com
Here Comes 'The Fed Is Meeting' Folly, Right on Schedule Mar 09 2017 
Francis Chou Adds to Valeant, Trims Sears in 4th Quarter Feb 16 2017 
ANGEL Program Gets National Attention Feb 13 2017 
Insider Buys Highlight for Week of Feb. 6 Feb 12 2017 
Insider Trades Roundup: Arconic, Walgreens, Alphabet Feb 11 2017 
Is Troubled Retailer a Valid Value Stock? Feb 10 2017 
Walgreens, Rite Aid Reduce Price, Postpone Closing of Merger Jan 30 2017 
How to Consistently Lose Money With Dividend Stocks Jan 30 2017 
Low-Yield Dividend Stocks Belong in Your Portfolio Jan 19 2017 
2 Top Health Care Dividend Stocks Jan 12 2017 

More From Other Websites
The Yuuuge Trumpcare Defeat Means Little to This Drug Retailing Giant Mar 29 2017
Walgreens Flu Index™ for Week of March 26, 2017 Mar 29 2017
Wall Street Optimistic on Walgreens ahead of Fiscal 2Q17 Results Mar 29 2017
Walgreens’s Fiscal 2Q17 Bottom Line to Benefit from Cost Control Mar 28 2017
Walgreens Boots Alliance: Top-Line Growth to Stay Muted in 2Q17 Mar 28 2017
Walgreens Is Ready to Report Fiscal 2Q17 Earnings: What to Expect Mar 28 2017
Baird Updates Its View On Walgreen's With New Rite-Aid Assumptions Mar 27 2017
Rupert Murdoch reportedly shed $125M Theranos stake for $1 Mar 24 2017
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Amgen, Walgreens Boots Alliance, General... Mar 24 2017
Walgreen Boots Buyout of Rite Aid Delayed, Other Woes Remain Mar 24 2017
Stock Research Reports for Amgen, Berkshire & Walgreens Mar 23 2017
Verizon, Colgate, Walgreens, Shell Are Breaking Out: Must-See Charts Mar 23 2017
New Product Launches May Boost Valeant’s Dermatology Revenue Mar 23 2017
Walgreens Flu Index™ for Week of March 19, 2017 Mar 22 2017
Partisan Politics May Be To Blame For Hold Up In Walgreens-Rite Aid Deal Mar 22 2017
Rite Aid Shares Could Slide 53% if WBA-RAD Falls Apart Mar 22 2017
The WBA-RAD Merger and the 43% Fall in Rite Aid Stock Mar 21 2017
What’s Happened since the Walgreens–Rite Aid October 2015 Deal? Mar 21 2017
Rite Aid Stock Could Dive 53% If Walgreens Deal Fails: Deutsche Bank Mar 21 2017
Walgreens–Rite Aid Merger Deal: The Drama and the Wait Mar 21 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)